GPR137C activators function through a variety of biochemical mechanisms to enhance the receptor's activity within cellular signaling pathways. Compounds that elevate intracellular cyclic AMP (cAMP) levels exert a profound effect on this G protein-coupled receptor. These activators achieve this by directly stimulating adenylate cyclase or by engaging beta-adrenergic receptors, which in turn activate protein kinase A (PKA). PKA then phosphorylates target proteins, including GPR137C, culminating in its enhanced functional state. Additionally, certain activators operate by modulating intracellular calcium concentrations. These activators may either increase calcium influx by binding to muscarinic acetylcholine receptors and L-type calcium channels, or decrease it through the inhibition of calcium channels. The resultant alteration in calcium-dependent signaling is another route through which GPR137C can be activated, as cellular mechanisms respond to maintain homeostasis, potentially involving the receptor in the compensatory response.
Other activators of GPR137C work by influencing secondary messenger pathways or ion channel activity. For instance, diacylglycerol analogs activate protein kinase C (PKC), which is known to phosphorylate various substrates that could include components of pathways relevant to GPR137C. In a similar vein, antagonism of excitatory neurotransmission or inhibition of cyclooxygenase enzymes triggers a cascade of cellular adjustments with possible upregulation of GPR137C activity being part of the compensatory mechanism. Additionally, the modulation of TRPV1 cation channels by certain ligands results in increased calcium influx, thereby potentially affecting GPR137C indirectly through calcium-sensitive pathways. Finally, compounds that inhibit the breakdown of cAMP ensure sustained PKA activity, which might contribute to the activation of GPR137C through prolonged activation of cAMP-dependent pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
This diterpene acts directly on adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels within the cell. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate and activate GPR137C. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
A synthetic catecholamine and beta-adrenergic agonist that increases intracellular cAMP levels by activating adrenergic receptors, subsequently activating PKA, which can target and activate GPR137C. | ||||||
Pilocarpine | 92-13-7 | sc-479256 | 100 mg | $250.00 | 1 | |
A muscarinic acetylcholine receptor agonist which can increase intracellular calcium levels through Gq protein signaling, potentially leading to the activation of calcium-sensitive pathways that modulate GPR137C activity. | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $120.00 $275.00 $380.00 $670.00 $1400.00 $3000.00 | 12 | |
A non-selective cholinergic agonist that, similarly to pilocarpine, can increase intracellular calcium levels through muscarinic receptors, affecting calcium-dependent mechanisms that may activate GPR137C. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $204.00 | 2 | |
An AMPA receptor antagonist that, by inhibiting excitatory neurotransmission, can lead to compensatory cellular mechanisms which may include the upregulation and activation of GPR137C. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
A calcium channel blocker that by reducing calcium influx, indirectly influences intracellular signaling pathways that may compensate by increasing GPR137C activity. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
An inhibitor of Gi/o proteins that, by preventing the inhibition of adenylate cyclase, can lead to increased cAMP levels and PKA activity, potentially upregulating and activating GPR137C. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $82.00 $192.00 $801.00 | ||
A calcium channel agonist that specifically increases L-type calcium channel activity, potentially enhancing the calcium-dependent activation of pathways involving GPR137C. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
Inhibits cyclooxygenase enzymes, leading to altered prostaglandin levels, which may modulate GPR137C activity through downstream effects on cellular signaling cascades. | ||||||
Capsaicin | 404-86-4 | sc-3577 sc-3577C sc-3577D sc-3577A | 50 mg 250 mg 500 mg 1 g | $94.00 $173.00 $255.00 $423.00 | 26 | |
Activates transient receptor potential vanilloid 1 (TRPV1) cation channels, leading to calcium influx and activation of calcium-dependent signaling pathways that could indirectly activate GPR137C. | ||||||